Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)
Keros Therapeutics (KROS) posted Depreciation & Amortization (CF) of $400000.0 for Q4 2025, up 1.27% on a QoQ basis from $395000.0 in Q3 2025, and up 20.48% year-over-year from $332000.0 in Q4 2024.
Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025) Analysis & Trends
Keros Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $400000.0 for Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 20.48% year-over-year to $400000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (up 22.78% YoY) and the FY2025 annual result came in at $1.5 million, up 22.78% from the prior year.
- Depreciation & Amortization (CF) was $400000.0 for Q4 2025 at Keros Therapeutics, up from $395000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $400000.0 in Q4 2025 and bottomed at $80000.0 in Q1 2021.
- A 5-year average of $230250.0 and a median of $228500.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) surged 238.46% — and 2023, when it slumped 37.99%.
- Keros Therapeutics' Depreciation & Amortization (CF) stood at $104000.0 in 2021, then grew by 22.12% to $127000.0 in 2022, then surged by 94.49% to $247000.0 in 2023, then jumped by 34.41% to $332000.0 in 2024, then rose by 20.48% to $400000.0 in 2025.
- Business Quant data shows KROS's Depreciation & Amortization (CF) at $400000.0 in Q4 2025, $395000.0 in Q3 2025, and $370000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | 400,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Sep 30, 2025 | 395,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Mar 31, 2025 | 344,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Dec 31, 2024 | 332,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Sep 30, 2024 | 315,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Jun 30, 2024 | 305,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Mar 31, 2024 | 277,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Dec 31, 2023 | 247,000.00 |
| Sep 30, 2023 | 210,000.00 |
| Sep 30, 2023 | 210,000.00 |